Evidence-Based Complementary and Alternative Medicine / 2013 / Article / Tab 5

Research Article

Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study

Table 5

Comparison of the main outcome measures within and between ZSQ and control groups.

Outcome measuresZSQ ( )Control ( )
MeanSDWithin-group
valuea
MeanSDWithin-group
valuea
Between-group
valueb

SLEDAI scores
 Baseline10.52.210.62.10.35
 Endpoint (12-week)5.11.5<0.017.01.9<0.010.03
CMS scores
 Baseline19.53.919.73.90.80
 Endpoint (12-week)12.34.3<0.0114.65.2<0.010.04
Mean prednisone dosage
 Baseline10.26.411.06.60.39
 Endpoint (12-week) 3.63.1<0.016.65.6<0.010.01
Mild-to-moderate flare-up at endpoint ( , %)5 (11.9) 8 (19.0)0.02
Severe flare-up0 (0.0)0 (0.0)
Anti-dsDNA (IU/mL)
 Baseline89.872.989.280.50.63
 Endpoint (12-week)76.361.6<0.0183.472.60.08<0.01
C3 (g/L)
 Baseline0.80.30.80.20.47
 Endpoint (12-week)1.20.30.020.80.30.270.02
C4 (g/L)
 Baseline0.20.10.30.10.61
 Endpoint (12-week)0.30.20.040.20.10.270.04
IgG (g/L)
 Baseline18.75.417.92.80.38
 Endpoint (12-week)17.05.0<0.0117.83.20.660.03
NK cell activity (%)
 Baseline14.58.814.06.20.78
 Endpoint (12-week)16.79.1<0.0116.34.2<0.010.29
sIL-2R (pM)
 Baseline40.88.640.114.80.80
 Endpoint (12-week)37.212.5<0.0138.613.8<0.010.11

aResults from paired -test to examine the effects of within-group, baseline versus 12-week, and 12-week versus 3-month followup.
bResults from an analysis of covariance (ANCOVA) with baseline as covariate, ZSQ group versus control group.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.